Drug Profile
Research programme: antibacterials - Glykoz
Latest Information Update: 19 Jan 2011
Price :
$50
*
At a glance
- Originator Glykoz
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 25 Sep 2005 This programme is still in active development at the lead optimisation stage - BIO-2005 Annual International Convention (BIO-2005)
- 26 Jul 2004 Compounds resulting from this discovery and development programme are available for licensing (http://www.glykoz.com/)
- 26 Jul 2004 Optimisation and preclinical trials in Bacterial infections (unspecified route)